Entering text into the input field will update the search result below

Moderna announces open IND for Propionic Acidemia program

Sep. 30, 2019 8:09 AM ETModerna, Inc. (MRNA) StockBy: SA News Team
  • The FDA has completed the review of Moderna's (NASDAQ:MRNA) IND application for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia (PA) and allowed it to proceed to clinic.
  • Moderna plans to initiate an open-label Phase 1/2 study of multiple ascending doses of mRNA-3927 in primarily pediatric patients with PA in U.S. and Europe. The objectives of this study are to evaluate the safety and tolerability of mRNA-3927 administered via IV infusion, characterize the pharmacokinetic profile of mRNA-3927 and assess the pharmacodynamic response as assessed by changes in plasma biomarkers.
  • This is the second rare disease candidate from Moderna’s pipeline with an open IND.

Recommended For You

More Trending News

About MRNA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRNA--
Moderna, Inc.